Ultragenyx Pharmaceutical, Inc. Investigated by the Portnoy Law Firm

Core Viewpoint - The Portnoy Law Firm has initiated an investigation into Ultragenyx Pharmaceutical, Inc. for possible securities fraud following the failure of its clinical trials, which has led to a significant drop in the company's stock price [1][3]. Group 1: Company Performance - On December 29, 2025, Ultragenyx announced that its Phase III Orbit and Cosmic studies for setrusumab (UX143) did not meet their primary endpoint of reducing annualized clinical fracture rates compared to placebo and biophosphonates [3]. - Although the studies showed improvements in secondary endpoints related to bone material density, these did not correlate with a statistically significant reduction in fractures [3]. - Following the announcement, Ultragenyx's stock price fell by $14.87 (43.49%) to open at $19.32 per share, marking a new 52-week low, significantly below the previous low of $25.81 [3]. Group 2: Legal Actions - The Portnoy Law Firm is representing investors in pursuing claims related to corporate wrongdoing, and has a history of recovering over $5.5 billion for aggrieved investors [3]. - Investors are encouraged to contact the firm for a complimentary case evaluation and to discuss their legal rights regarding potential claims [2].